Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 5 of 5 descriptions
| No. | 薬物名（臨床試験情報から抽出） | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Denosumab | 1件: Denosumab Denosumab (Denosumab) | 1件: Denosumab
Denosumab
(Denosumab, Denosumab) 💬1. Denosumab
| 1件: TNFSF11 TNFSF11 💬1. Denosumab
| 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 8件: Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interac ... | 8件: 46 46, 50, 70, 93, 95, 96, 274, 299 💬
| ||||||||||||||
| 2 | Denosumab - - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand | 1件: Denosumab Denosumab (Denosumab) | 1件: Denosumab
Denosumab
(Denosumab, Denosumab) 💬2. Denosumab - - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand
| 1件: TNFSF11 TNFSF11 💬2. Denosumab - - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand
| 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 8件: Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interac ... | 1件: 274 274 💬2. Denosumab - - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand
| ||||||||||||||
| 3 | Denosumab - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand | 1件: Denosumab Denosumab (Denosumab) | 1件: Denosumab
Denosumab
(Denosumab, Denosumab) 💬3. Denosumab - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand
| 1件: TNFSF11 TNFSF11 💬3. Denosumab - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand
| 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 8件: Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interac ... | 1件: 274 274 💬3. Denosumab - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand
| ||||||||||||||
| 4 | PRALIA 60 mg Subcutaneous Injection Syringe(denosumab) | 1件: Denosumab Denosumab (Denosumab) | 1件: Denosumab
Denosumab
(Denosumab, Denosumab) 💬4. PRALIA 60 mg Subcutaneous Injection Syringe(denosumab)
| 1件: TNFSF11 TNFSF11 💬4. PRALIA 60 mg Subcutaneous Injection Syringe(denosumab)
| 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 8件: Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interac ... | 1件: 46 46 💬4. PRALIA 60 mg Subcutaneous Injection Syringe(denosumab)
| ||||||||||||||
| 5 | PRALIA 60mg Subcutaneous Injection Syringe(denosumab) | 1件: Denosumab Denosumab (Denosumab) | 1件: Denosumab
Denosumab
(Denosumab, Denosumab) 💬5. PRALIA 60mg Subcutaneous Injection Syringe(denosumab)
| 1件: TNFSF11 TNFSF11 💬5. PRALIA 60mg Subcutaneous Injection Syringe(denosumab)
| 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 8件: Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interac ... | 1件: 46 46 💬5. PRALIA 60mg Subcutaneous Injection Syringe(denosumab)
|